ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "GAIA-CLL13 & COSMIC-313"
Episode Synopsis
Today's Pod discusses...
1) A large trial comparing 4 different CLL treatments
GAIA-CLL13: https://www.nejm.org/doi/full/10.1056/NEJMoa2213093
2)Adding Cabozantinib + Nivo/Ipo vs. Nivo/Ipi in intermediate/poor risk mRCC
COSMIC-313: https://www.nejm.org/doi/full/10.1056/NEJMoa2212851
3) A potential future biomarker for predicting response to PD-(L)1 targeted therapies
Functional PD-1/PD-L1 Engagement: https://pubmed.ncbi.nlm.nih.gov/?term=36821809
1) A large trial comparing 4 different CLL treatments
GAIA-CLL13: https://www.nejm.org/doi/full/10.1056/NEJMoa2213093
2)Adding Cabozantinib + Nivo/Ipo vs. Nivo/Ipi in intermediate/poor risk mRCC
COSMIC-313: https://www.nejm.org/doi/full/10.1056/NEJMoa2212851
3) A potential future biomarker for predicting response to PD-(L)1 targeted therapies
Functional PD-1/PD-L1 Engagement: https://pubmed.ncbi.nlm.nih.gov/?term=36821809
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust